戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  potassium citrate or potassium citrate plus chlorthalidone.
2 alidone, but not with potassium citrate plus chlorthalidone.
3 to continue hydrochlorothiazide or switch to chlorthalidone.
4 otassium chloride, or potassium citrate plus chlorthalidone.
5 th chlorthalidone and potassium citrate plus chlorthalidone.
6 signed to receive amlodipine, lisinopril, or chlorthalidone.
7 ted in independent participants treated with chlorthalidone.
8 -responders to hydrochlorothiazide (HCTZ) or chlorthalidone.
9 e/bicarbonate exchange with acetazolamide or chlorthalidone.
10 potassium intake), or potassium citrate plus chlorthalidone.
11  Hg higher than that in patients assigned to chlorthalidone.
12 to be twice as high with doxazosin than with chlorthalidone.
13 l (telmisartan 20 mg, amlodipine 2.5 mg, and chlorthalidone 12.5 mg) therapy vs usual care.
14                                              Chlorthalidone (12.5 to 25 mg/d) or doxazosin (2 to 8 mg
15 ve drug therapy, in which the step 1 drug is chlorthalidone (12.5-25 mg) or matching placebo, and the
16 sinopril (10-40 mg/d) arms compared with the chlorthalidone (12.5-25 mg/d) arm.
17 ndomized to placebo or active treatment with chlorthalidone (12.5-25 mg/d), with atenolol (25-50 mg/d
18 ctive treatment group received a low dose of chlorthalidone (12.5-25.0 mg/d) with a step-up to atenol
19 ed after a baseline period and after 2 wk of chlorthalidone (25 mg), amiloride (5 mg), and the two di
20 lcium antagonist (amlodipine), (4) diuretic (chlorthalidone), (5) alpha1-antagonist (doxazosin), and
21 eline diabetes, incident diabetes (7.5% with chlorthalidone, 5.6% with amlodipine, and 4.3% with lisi
22 he CC genotype showed larger reductions with chlorthalidone (-6.5 mm Hg) than with amlodipine (-3.8 m
23                      Treatment with low-dose chlorthalidone, 6.25 mg daily, significantly reduced mea
24                          This study compared chlorthalidone, 6.25 mg daily, with HCTZ, 12.5 mg daily,
25  with stage 1 hypertension to receive either chlorthalidone, 6.25 mg, (n = 16); HCTZ 12.5 mg (n = 18)
26                               Thus, low-dose chlorthalidone, 6.25 mg, could be used as monotherapy fo
27                                              Chlorthalidone alone (P < 0.002) and the combination of
28 0% of subjects were receiving treatment with chlorthalidone alone by the end of years 1 and 3, respec
29                                              Chlorthalidone alone improved bone quality, but adding p
30                                              Chlorthalidone also reduced the incidence of new-onset H
31                Neither potassium citrate nor chlorthalidone altered stone formation.
32 /79, 139/79, and 140/80 mm Hg in those given chlorthalidone, amlodipine, and lisinopril.
33                         Medications included chlorthalidone, amlodipine, carvedilol, cholecalciferol,
34 ermined in 37 939 participants randomized to chlorthalidone, amlodipine, lisinopril, or doxazosin tre
35 isk hypertensive patients were randomized to chlorthalidone, amlodipine, lisinopril, or doxazosin, pr
36 tack Trial) data, which randomized adults to chlorthalidone, amlodipine, or lisinopril.
37                         Random assignment to chlorthalidone, amlodipine, or lisinopril.
38 et, death occurred in 29.2% of participants (chlorthalidone/amlodipine/lisinopril) with new-onset HFP
39 like diuretic such as hydrochlorothiazide or chlorthalidone, an angiotensin-converting enzyme inhibit
40 mL/min/1.73 m2), including 2936 who received chlorthalidone and 9786 who received hydrochlorothiazide
41 one alone (P < 0.002) and the combination of chlorthalidone and amiloride (P < 0.003) reduced calcium
42 the TT homozygous individuals when comparing chlorthalidone and amlodipine (CHD: CC = 0.86; TC = 0.90
43 ignificant differences were observed between chlorthalidone and hydrochlorothiazide for dialysis or k
44 oject, a randomized clinical trial comparing chlorthalidone and hydrochlorothiazide for the treatment
45 ochlorothiazide, and two thiazide-like drugs chlorthalidone and indapamide, revealing that they fit i
46 he most widely used thiazide-like diuretics, chlorthalidone and indapamide, using cryogenic electron
47 .8 and 11.7 mg/dL], respectively), less with chlorthalidone and placebo (0.12 and 0.13 mmol/L [4.5 an
48      Using this rat model, we tested whether chlorthalidone and potassium citrate combined would redu
49                              To test whether chlorthalidone and potassium citrate combined would redu
50     Vertebral trabecular bone increased with chlorthalidone and potassium citrate plus chlorthalidone
51  for amlodipine and lisinopril compared with chlorthalidone, and 10-year adjusted rates of 86%, 87%,
52 azolamide, ethoxyzolamide, dichlorphenamide, chlorthalidone, and furosemide were not effective in viv
53                        No stones formed with chlorthalidone, and rats given potassium citrate plus ch
54 s in PC12 cells; and (3) that acetazolamide, chlorthalidone, and the neurosteroid, allopregnanolone,
55 revent Heart Attack Trial (ALLHAT), low-dose chlorthalidone as the first-line drug was superior to do
56 apy with hydrochlorothiazide or to switch to chlorthalidone at a daily dose of 12.5 or 25 mg.
57 essure monitoring, in a 1:1 ratio to receive chlorthalidone at an initial dose of 12.5 mg per day, wi
58 1985 and 1990, antihypertensive therapy with chlorthalidone-based stepped-care therapy resulted in a
59 ferentially expressed in relation to HCTZ or chlorthalidone BP response in whites.
60            Cortical bone area increased with chlorthalidone but not potassium citrate or potassium ci
61 d nighttime BP (p < 0.01) were observed with chlorthalidone but not with HCTZ.
62 tify those who may have greater benefit from chlorthalidone, but future research is needed to determi
63                     We previously found that chlorthalidone, but not potassium citrate, decreased sto
64  properties of trabecular bone improved with chlorthalidone, but not with potassium citrate plus chlo
65                                         With chlorthalidone, calcium excretion fell to normal (<4.0 m
66 e increases in plasma total cholesterol with chlorthalidone compared with placebo at 12 months were n
67  approximately 3.5 mm Hg-greater response to chlorthalidone compared with those at an intermediate ge
68                                              Chlorthalidone (CTD) is more potent than hydrochlorothia
69  compare HCTZ with the uncommonly prescribed chlorthalidone (CTDN) in reducing cardiovascular events
70                       Potassium citrate plus chlorthalidone decreased urine oxalate compared to all o
71  in clinical practice, patients who received chlorthalidone did not have a lower occurrence of major
72 urine calcium phosphate supersaturation, but chlorthalidone did not.
73 tment initiated with doxazosin compared with chlorthalidone doubled the risk for heart failure in hig
74 1; median follow-up, 1.74 years); and in the chlorthalidone/doxazosin comparison that was terminated
75 ive risks of amlodipine or lisinopril versus chlorthalidone during year 1 were 2.22 (1.69 to 2.91; <0
76 educed it further and potassium citrate plus chlorthalidone even further.
77 on, stepped-care treatment based on low-dose chlorthalidone exerted a strong protective effect in pre
78 acetaminophen, ibuprofen) to not degradable (chlorthalidone, fluconazole).
79 rrence of primary-outcome events between the chlorthalidone group (702 patients [10.4%]) and the hydr
80 fidence interval [CI], -13.9 to -8.1) in the chlorthalidone group and -0.5 mm Hg (95% CI, -3.5 to 2.5
81 ic blood pressure was 142.6 8.1 mm Hg in the chlorthalidone group and 140.1 8.1 mm Hg in the placebo
82 , when mean plasma total cholesterol for the chlorthalidone group fell below baseline.
83 e incidence of hypokalemia was higher in the chlorthalidone group than in the hydrochlorothiazide gro
84 o from baseline to 12 weeks was lower in the chlorthalidone group than in the placebo group by 50 per
85 yperuricemia occurred more frequently in the chlorthalidone group than in the placebo group.
86  systolic ABP was significantly lower in the chlorthalidone group than in the the HCTZ group.
87  (HR, 1.46; 95% CI, 1.09-1.96), but those on chlorthalidone had significantly lower risk than those o
88 idone, and rats given potassium citrate plus chlorthalidone had some stones but fewer than controls.
89 ent AF or atrial flutter (AFL) compared with chlorthalidone in a large clinical trial cohort with ext
90 as reduced by chlorthalidone (P <.04) and by chlorthalidone in combination with amiloride (P <.02).
91                     As typically prescribed, chlorthalidone in older adults was not associated with f
92                    Lisinopril was similar to chlorthalidone in preventing CHD (15.1% vs. 15.2%, respe
93 her amlodipine nor lisinopril is superior to chlorthalidone in preventing CHD, stroke, or combined CV
94  to potassium citrate alone or combined with chlorthalidone in reducing calcium phosphate stone forma
95                    Amlodipine was similar to chlorthalidone in reducing CHD (16.0% vs. 15.2%, respect
96  was not superior to thiazide-like diuretic (chlorthalidone) in preventing coronary heart disease (CH
97                                              Chlorthalidone increased urine citrate and potassium cit
98             Potassium citrate, alone or with chlorthalidone, increased urine calcium phosphate supers
99                                              Chlorthalidone is a potent, long-acting thiazide-like di
100 failure while taking doxazosin compared with chlorthalidone is attenuated but not eliminated by addin
101 preventing CHD, stroke, or combined CVD, and chlorthalidone is superior to both for preventing heart
102                                      Whether chlorthalidone is superior to hydrochlorothiazide for pr
103 n genetic hypercalciuric stone-forming rats, chlorthalidone is superior to potassium citrate alone or
104 coronary heart disease, was identical in the chlorthalidone, lisinopril, and amlodipine groups.
105 pulated assessment of the relative effect of chlorthalidone, lisinopril, and amlodipine in preventing
106                  Some evidence suggests that chlorthalidone may be superior to hydrochlorothiazide fo
107 randomized to the treatment groups of either chlorthalidone (n = 3745) or lisinopril (n = 2294), with
108 ere randomly assigned to receive a diuretic (chlorthalidone; n = 13,860), a calcium antagonist (amlod
109 6 years or older who were newly treated with chlorthalidone or hydrochlorothiazide and were not hospi
110  adults aged 66 years or older who initiated chlorthalidone or hydrochlorothiazide during this period
111  suggest that there is no evidence to prefer chlorthalidone over hydrochlorothiazide.
112        Mean citrate excretion was reduced by chlorthalidone (P <.04) and by chlorthalidone in combina
113 ted in independent participants treated with chlorthalidone (P=0.04).
114 s initially prescribed 12.5, 25, or 50 mg of chlorthalidone per day with those prescribed 12.5, 25, o
115 sium chloride as control, potassium citrate, chlorthalidone plus potassium chloride, or potassium cit
116 late stone formation, potassium citrate plus chlorthalidone prevented stone formation better than eit
117                                Compared with chlorthalidone, randomization to either lisinopril (haza
118                                         Each chlorthalidone recipient was matched to up to 2 hydrochl
119                            During follow-up, chlorthalidone recipients (n = 10 384) experienced the p
120 duced it further, and potassium citrate plus chlorthalidone reduced it even more.
121 , potassium citrate reduced urinary calcium, chlorthalidone reduced it further and potassium citrate
122 educed urine calcium compared with controls, chlorthalidone reduced it further, and potassium citrate
123                                              Chlorthalidone reduced the risk of HFPEF compared with a
124                                              Chlorthalidone reduced the risk of HFREF compared with a
125 tan, but not with the thiazide-type diuretic chlorthalidone, restored sympatholysis in the hypertensi
126 pertension, thiazide diuretics, particularly chlorthalidone, should be considered as one of the initi
127              However, potassium citrate plus chlorthalidone significantly reduced stone formation.
128        In ALLHAT, with adjudicated outcomes, chlorthalidone significantly reduced the occurrence of n
129 igned to receive treatment with 12.5 mg/d of chlorthalidone (step 1); either 25 mg/d of atenolol or 0
130 tment of isolated systolic hypertension with chlorthalidone stepped-care therapy for 4.5 years was as
131  (consisting of amlodipine, telmisartan, and chlorthalidone) than in those receiving usual care in Sr
132  disease and poorly controlled hypertension, chlorthalidone therapy improved blood-pressure control a
133       In patients with Dent's disease during chlorthalidone therapy, the supersaturation ratios for c
134 alyses of participants continuing to receive chlorthalidone throughout the 4 years of follow-up indic
135                         Half of the rats had chlorthalidone (Thz; 4 to 5 mg/kg per d) added to their
136 3745 Black GenHAT participants randomized to chlorthalidone treatment, median (IQR) participant age w
137                     Low-dose diuretic-based (chlorthalidone) treatment is effective in preventing maj
138                                Compared with chlorthalidone, treatment with lisinopril is not associa
139                                              Chlorthalidone use was also associated with a higher ris
140                                              Chlorthalidone use was associated with a higher risk of
141  cohort study found that among older adults, chlorthalidone use was associated with a higher risk of
142                                          New chlorthalidone users were matched 1:4 with new hydrochlo
143 e binding energy and most hydrogen bonds are chlorthalidone, valdecoxib, and ZINC14824819, which inte
144                       HF risk decreased with chlorthalidone versus amlodipine or lisinopril use durin
145 sequently, risk for those individuals taking chlorthalidone versus amlodipine remained decreased but
146 ry requiring hospitalization (391 [6.4%] for chlorthalidone vs 379 [6.2%] for hydrochlorothiazide; P
147 he incidence of CKD (961 of 4520 [21.3%] for chlorthalidone vs 939 of 4518 [20.8%] for hydrochlorothi
148 ting risks examined the associations between chlorthalidone vs hydrochlorothiazide use and the outcom
149 icant increased incidence of hypokalemia for chlorthalidone vs hydrochlorothiazide was observed (545
150 risk for heart failure with doxazosin versus chlorthalidone was 3.10 (CI, 2.51 to 3.82) and 1.42 (CI,
151          The excess risk of hypokalemia with chlorthalidone was attenuated in participants with reduc
152                                              Chlorthalidone was not superior to hydrochlorothiazide a
153                                              Chlorthalidone was not superior to hydrochlorothiazide f
154                                              Chlorthalidone was similar to lisinopril with regard to
155 P values) of amlodipine or lisinopril versus chlorthalidone were 1.35 (1.21 to 1.50; <0.001) and 1.11
156                        Patients treated with chlorthalidone were more likely to be hospitalized with
157                              Participants on chlorthalidone with incident diabetes versus no diabetes
158                                   Rats given chlorthalidone with or without potassium citrate had hig
159 um chloride (as control), potassium citrate, chlorthalidone (with potassium chloride to equalize pota
160 st the hypothesis that the thiazide diuretic chlorthalidone would decrease urine calcium excretion, s

 
Page Top